Evidence map›Paper›PMID 36002192›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib].

Qing Zhou, Shun Lu, Yong Li, Fujun Jia, Guanjun Li, Zhen Hong, You Lu, Yun Fan, Jianying Zhou, Zhe Liu and 4 more

Open access · greenAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Qing Zhou *Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Shun Lu *Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Yong LiDepartment of Cardiology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Fujun JiaDepartment of Psychiatry, Guangdong Mental Health Center, Guangzhou 510120, China.
Guanjun LiDepartment of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Zhen HongDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.
You LuDepartment of Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Yun FanDepartment of Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Jianying ZhouDepartment of Respiratory Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Zhe LiuDepartment of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Juan LiDepartment of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
Yi-Long WuGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Chinese Thoracic Oncology Group (CTONG)
Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib Workgroup
Huashan Hospital · CNCapital Medical University · CNGuangdong Academy of Medical Sciences · CNGuangdong Provincial People's Hospital · CNShanghai Jiao Tong University · CNSichuan Cancer Hospital · CNSichuan University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy.
.

Indexed as

Carcinoma, Non-Small-Cell LungDrug-Related Side Effects and Adverse ReactionsLung NeoplasmsAminopyridinesChinaConsensusDrug Resistance, NeoplasmHumansLactamsLactams, MacrocyclicProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesAminopyridinesLactamsLactams, MacrocycliclorlatinibProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesAdverse eventAnaplastic lymphoma kinaseLorlatinibLung neoplasms

Identifiers

PMID36002192
PMCPMC9411957
OpenAlexW4293102209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.